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Abstract 
We  describe  the  clinicopathological  and
morphological features of an unusual breast
carcinoma classifiable as a lipid-rich variant of
ductal invasive carcinoma, with a basal-type
immunohistochemical  profile.  Basal-type
breast  cancers  show  no  hormonal  receptor
expression,  rarely  over-express  HER-2  but
exhibit  molecular  high  weight  cytokeratins,
EGFR and c-kit positivity. Special stains and
histochemistry tests were used to elucidate the
nature  of  vescicles  in  the  neoplastic  cells.
Sudan IV was performed on formalin-fixed tis-
sue. Commercially available antibodies tested
were: ER, PgR, EGFR, HER2, c-kit, high molec-
ular  weight  cytokeratins.  Cytoplasmic  lipids
were  highlighted  as  red-orange  droplets  on
Sudan IV staining. As for immunohistochem-
istry, the tumor showed no reactivity to ER,
PgR and HER2 (triple negative), and diffuse
and strong positivity to high weight cytoker-
atins,  EGFR  and  c-kit,  such  as  a  basal-type
breast carcinoma. A basaloid phenotype in a
lipid-rich carcinoma has not been previously
reported.
Introduction
Breast  cancer  represents  a  heterogeneous
group of tumoral entities, associated with spe-
cific morphological changes and immunohisto-
chemical features: the clinical presentation and
molecular alterations make it a highly diverse
disease.  That  is  why  patients  with  the  same
tumor types and staging respond differently to
treatment and do not share the same prognosis.
Lipid-rich invasive breast cancer is a rare enig-
matic entity among special types of infiltrating
duct carcinoma, with difficult diagnosis.
1
Only a few cases are reported in the litera-
ture.
2 Tumor cells contain abundant intracyto-
plasmatic lipids.
3
Lipid-rich carcinoma was first described in
women  by  Aboumrad  et  al.
4 These  authors
thought that the lipid droplets were produced
and  secreted  by  the  tumor  cells  instead  of
being  the  result  of  regressive  degeneration
because  lipid  droplets  existed  uniformly  in
metastasized lymph nodes and in tumor cells
undergoing mitosis.
5
Since there was great heterogeneity in clin-
ical outcome for estrogen positive tumors com-
pared to the uniform behavior of hormone neg-
ative  tumors,
6 researchers  have  invested  in
molecular aspects of breast cancer by investi-
gating biological markers.
7
Recent literature
8 suggests a new classifica-
tion of breast cancer, based on its biological
features  and  categorizes  tumors  according
their  immunophenotype  in  a  luminal  and  a
basal-type,
9 corresponding to two distinct types
of epithelial cells found in the normal mamma-
ry gland.
Basal-type breast tumors show no hormonal
receptor expression, rarely over-express HER-2
(triple  negative)  but  show  high-molecular
weight cytokeratins, EGFR and  c-kit positivity.
It was suggested
10 that the heterogeneity of
breast cancer may be derived from the diversi-
ty of the original cells for neoplastic transfor-
mation, which is thought to exist in the termi-
nal duct lobular unit of the mammary gland. 
The cells in the terminal duct lobular unit
consist of glandular, basal and myoepithelial
cells. This heterogeneous population of epithe-
lial cells arises from a common progenitor but
they  each  express  unique  markers  and  per-
form unique functions. 
The paradigm that breast cancer is a hetero-
geneous  disease  shifts  to  the  new  one  that
breast cancer is at least two different diseases
with age-specific incidence. Estrogen-negative
tumors usually consist of high-grade, aggres-
sive tumors or rare histoypes (adenoid cystic,
metaplastic).  The  basal-like  subtype  has  an
interval  presentation  and  it  is  not  usually
detected during a mammographic screening.
11
We  describe  the  clinicopathological  and
morphological features of an unusual breast
carcinoma classifiable as a “lipid-rich” variant
of ductal invasive carcinoma and correlate it
with a basal immunohistochemical profile.
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Figure  1.  Fine  nee-
dle aspiration cytol-
ogy:  Large,  vac-
uolized cells. 400X.[Rare Tumors 2009; 1:e41] [page 125]
Materials and Methods
A  73-year  old  woman,  previously  in  good
health, in menopause since she was 38 years
old,  presented  with  a  sudden  breast  mass.
Mammography  performed  10  months  earlier
was negative.
Imaging  studies  further  evaluated  the
extent of the disease: CT scan revealed no evi-
dence of metastatic disease.
The patient was treated at the Breast Unit of
Pellegrini Hospital (Naples, Italy). She under-
went a modified radical mastectomy with axil-
lary lymphadenectomy after a fine needle aspi-
ration  cytologic  diagnosis  of  carcinoma
(Figures 1 and 2). 
All  available  paraffin  blocks  or  unstained
sections were retrieved and the original hema-
toxylin  and  eosin-stained  sections  were
reviewed. After gross examination, the speci-
men was serially sectioned into 3 mm thick
slices and formalin-fixed. 
In addition, 9 invasive ductal carcinomas,
not otherwise specified were used as a control
group for histological and immunohistochemi-
cal correlations. Whole tissue sections (5 μm)
were  cut  and  used  for  histochemistry  and
immunohistochemistry.
The immunohistochemical stains were per-
formed  using  Ventana
® Benchmark™
Automated  Immunostainer  on  formalin-fixed
paraffin-embedded  specimens.  Commercially
available  antibodies  tested  were:  ER,  PgR,
EGFR, HER2, c-kit (Ventana, Tucson, AZ, USA),
high  molecular  weight  cytokeratins  (clone
34βE12-ORG-8735, Novocastra) all prediluted
according to the manufacturers’ instructions.
Peroxidase  activity  was  visualized  with
diaminobenzidine chromogen as per routine
protocol to obtain a brown-black end product.
Appropriate internal and external positive con-
trols were used. In an effort to elucidate the
nature of the vescicles, special stains and his-
tochemistry  tests  were  performed.  Sudan  IV
(modified by Coppola) method for fat: after fix-
ation  in  10%  buffered  neutral  formalin,  the
specimen was rinsed in water for 24 hours to
remove the excess. Then 10 micron frozen sec-
tions were cut, collected in distilled water and
stained in a Sudan IV solution (Sudan was dis-
solved in 70% alcohol). After that we mounted
slides with glycerin jelly (Figure 3). We chose
alcohol instead of Herxheimer solution, made
of alcohol and acetone, to avoid an excessive
extraction since we dealed with previous for-
malin that is a fat solvent. 
Results
On gross examination the tumor was firm
and  whitish  with  ill  defined  margins  and
measured 2.2 cm in diameter. On morphologi-
cal grounds it was a high-grade invasive ductal
carcinoma  with  an  80%  histiocyte-like  neo-
plastic component and a 15% in situ ductal car-
cinoma component .
The neoplastic cells, arranged in nests and
cords were medium-sized, with a small round,
dark,  nucleolatus nucleus and a large foamy
clear  cytoplasm  (Figure  4).  There  were  per-
ineural  invasion,  peritumoral  neoplastic
embolization  and  columnar  alteration  with
prominent  apical  snouts  and  secretion
(CAPSS) in uninvolved parenchima.
All the axillary  lymphnodes (fourteen) were
negative. We also observed some calcifications
and  a  mild  chronic  intra  and  peritumoral
inflammation.  No  reaction  with  Periodic
Acid–Schiff, Alcian and PAS-D histochemical
technique  was  observed  within  tumor  cells.
Cytoplasmic  lipids  were  highlighted  as  red-
orange droplets at the Sudan IV staining. In
agreement  with  the  current  morphological
description of human and canine tumors, the
cells we examined with large vacuoles of neu-
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Figure  2.  Fine  nee-
dle aspiration cytol-
ogy. E.E. 400X.
Figure  3.  Sudan  IV.
250X.
Figure 4.
Hematoxylin-Eosin.
250X.[page 126] [Rare Tumors 2009; 1:e41]
tral lipids were consistent with lipid-rich carci-
noma, a rare and distinct variant of infiltrative
ductal  breast  carcinoma  (lipid-rich  invasive
ductal carcinoma according to WHO classifica-
tion, 2003). As for immunohistochemistry, the
tumor  showed  no  reactivity  to  ER,  PgR  and
HER2 (triple negative), and diffuse and strong
positivity to high weight cytokeratins,
12 EGFR
(Figures 5 and 6) and c-kit (Figure 7), such as
a basal-type breast carcinoma.
Discussion
The foregoing data suggest that breast can-
cers show great diversity in their morpholo-
gies, clinical histories and responsiveness to
chemiotherapy.  This  wide  diversity  poses  a
challenge to provide accurate diagnostic, prog-
nostic and predictive information and effective
treatment. Traditional therapies targeting the
estrogen-receptors  or  HER2  oncogene  would
not be expected to be effective on basal-like
breast cancers because this subtype expresses
neither of these proteins.
“Breast cancer can no longer be viewed as
one biologic entity. If breast cancer overall con-
sists  of  at  least  two  main  types,  we  need  a
stratified  rather  than  a  unified  approach  to
breast cancer research, prevention and treat-
ment”.
13 Some  investigators  have  previously
suggested that basal-like carcinoma may con-
sist of components of invasive ductal carcino-
ma, not otherwise specified, metaplastic carci-
noma, and medullary carcinoma.
14
This is the first report of a lipid-rich breast
carcinoma with a basaloid phenotype.  
Even if, based on one case, definitive con-
clusions about pathogenic implications cannot
be reached, it is peculiar that we observed car-
cinoma  secreting  cells  showing  a  basaloid
immunoprofile,  since  the  secretory  function
usually belongs to luminal cells.
It is reasonable to conclude that this paper
may raise new questions, but it cannot give
ultimate results.
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